What Beijing said
China criticized the U.S. Treasury proposal as discriminatory and "a typical example of an overly broad application of national security concerns." The Ministry of Commerce said the plan conflicts with the "important consensus" the two presidents reached, adding it would damage China U.S. economic and trade cooperation and harm U.S. companies' interests. Beijing said it will monitor the situation closely and "reserves the right to take corresponding measures."
"China urges the US to respect the laws of the market economy, cease the overbroad application of the concept of national security, stop politicizing and weaponizing economic and trade issues, and create a favorable environment for China U.S. economic and trade cooperation," it said.
When policy choices affect global economic ties, staying informed matters, so sign up for the free Market Briefs today
What Washington is proposing
This week, the Trump administration moved to classify biotechnology alongside other areas where investments tied to foreign adversaries face restrictions, citing national security as the justification. It is the latest step in efforts to restrain China's biotech progress, a change that could make financial links more complex as U.S. drugmakers increasingly look to China for new medicines.
Why it matters for investors
The proposal could complicate financial ties between the two countries, and China said it may take corresponding measures in response. Beijing also cautioned that the plan would undermine economic and trade collaboration between the two nations and harm U.S. companies' interests. In plain English: rising policy friction around biotech and cross border capital is now a live variable for portfolios with China exposure.
Across complex trade and investment stories, get clarity each morning with our free Market Briefs newsletter in five minutes
